En undersøgelse af den kliniske effekt og sikkerheden af PRX-115 administreret intravenøst i forskellige doseringsregimer, med og uden methotrexat, versus placebo hos voksne patienter med gigt (RELEASE) (RELEASE)
Et multicenter, randomiseret, dobbeltblindt, placebokontrolleret, fase 2-studie, der vurderer effektiviteten, sikkerheden og valget af doseringsregime for flere intravenøse infusioner af PRX-115 med og uden metotrexat versus placebo hos voksne patienter med gigt (RELEASE)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This study will evaluate the efficacy, safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PRX-115 (a recombinant pegylated Uricase) in adult patients with gout. Participants will receive PRX-115 by intravenous (IV) infusions according to different treatment schedules, with and without the immunomodulator methotrexate (MTX).
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Head of Clinical Development
- Telefonnummer: +972-4-902-8100
- E-mail: info@protalix.com
Studiesteder
-
-
Arizona
-
Glendale, Arizona, Forenede Stater, 85306
- Rekruttering
- Rezen Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Rekruttering
- Applied Research Center of Arkansas
-
-
California
-
Anaheim, California, Forenede Stater, 92805
- Rekruttering
- Advanced Research Center, Inc
-
El Cajon, California, Forenede Stater, 91910
- Rekruttering
- Triwest Research Associates Llc
-
La Palma, California, Forenede Stater, 90623
- Rekruttering
- Imax Clinical Trials, LLC
-
Long Beach, California, Forenede Stater, 90806
- Rekruttering
- Kinetic Clinical Research
-
-
Florida
-
Clearwater, Florida, Forenede Stater, 33765
- Rekruttering
- Clinical Research of West Florida, Inc.
-
DeLand, Florida, Forenede Stater, 32720
- Rekruttering
- Accel Research Sites - Deland Clinical Research Unit
-
Doral, Florida, Forenede Stater, 33125
- Rekruttering
- ICR Sites East
-
Hialeah, Florida, Forenede Stater, 33010
- Rekruttering
- Qway Research
-
Miami, Florida, Forenede Stater, 33155
- Rekruttering
- Bioclinical Research Alliance, Inc
-
Miami, Florida, Forenede Stater, 33169
- Rekruttering
- D&H National Research Centers (North Miami)
-
Miami, Florida, Forenede Stater, 33173
- Rekruttering
- Well Pharma Medical Research Group
-
Orlando, Florida, Forenede Stater, 32832
- Rekruttering
- Conquest Research - Lake Nona
-
Orlando, Florida, Forenede Stater, 32897
- Rekruttering
- Combined Research Orlando Phase I-IV
-
Palmetto Bay, Florida, Forenede Stater, 33176
- Rekruttering
- New Horizons Research
-
Tampa, Florida, Forenede Stater, 33606
- Rekruttering
- Clinical Research of West Florida, Inc.
-
-
Georgia
-
Columbus, Georgia, Forenede Stater, 31904
- Rekruttering
- Centricity Research - Columbus Georgia Multispecialty
-
-
Michigan
-
Dearborn, Michigan, Forenede Stater, 48126
- Rekruttering
- Revival Research Institute, LLC
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Rekruttering
- Quest Research Institute
-
Sterling Heights, Michigan, Forenede Stater, 48313
- Rekruttering
- Revive Research Institute, Inc
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Forenede Stater, 16635
- Rekruttering
- Altoona Center for Clinical Research
-
-
Texas
-
Houston, Texas, Forenede Stater, 77099
- Rekruttering
- Pioneer Research Solutions Inc
-
Sugar Land, Texas, Forenede Stater, 77479
- Rekruttering
- Mt. Olympus Medical Research, LLC - Sugar Land
-
Waco, Texas, Forenede Stater, 76710
- Rekruttering
- Velocity Clinical Research
-
-
Virginia
-
Suffolk, Virginia, Forenede Stater, 23435
- Rekruttering
- Velocity Clinical Research
-
-
-
-
-
Tbilisi, Georgien, 0102
- Rekruttering
- Aleksandre Aladashvili Clinic LLC, Georgia
-
Tbilisi, Georgien, 0159
- Rekruttering
- Tbilisi Heart and Vascular Clinic Ltd , Georgia
-
Tbilisi, Georgien, 0160
- Rekruttering
- Mediclub Georgia
-
Tbilisi, Georgien, 0160
- Rekruttering
- Tbilisi Institute of Medicine, Georgia
-
Tbilisi, Georgien, 0172
- Rekruttering
- Georgian-Dutch Hospital, Georgia
-
Tbilisi, Georgien, 0180
- Rekruttering
- LTD First Medical Center, Georgia
-
-
-
-
-
Afula, Israel, 1834111
- Rekruttering
- HaEmek MC, Israel
-
Ashkelon, Israel, 7830604
- Rekruttering
- Barzilai MC, Israel
-
Kfar Saba, Israel, 4438164
- Rekruttering
- Meir MC, Israel
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Males or females ≥18 years of age.
- Weight within the range of 50.0 - 150.0 kg.
- Gout patients who failed to normalize sUA (<7 mg/dL) with or without xanthine oxidase inhibitors or uricosuric agent or have contraindications to these drugs.
- Willing to discontinue any oral ULT
- Females who are sterile, postmenopausal, or non-pregnant and using birth control methods.
Exclusion Criteria:
- Any condition known to have arthritis as a clinical manifestation.
- Positive testing for HBV,HCV, or HIV.
- The patient is a pregnant or lactating female or plans to become pregnant during the study period.
- Known allergy or sensitivity to the injected proteins, including pegylated products.
- Prior exposure to any experimental or marketed uricase.
- Patient treated with a medication known to have an influence on urate metabolism or clearance such as ULTs.
- History of anaphylaxis, severe allergic reactions, or severe atopy.
- G6PD deficiency or known catalase deficiency.
- History of significant hematologic or autoimmune disorders within 5 years of Screening and/or patient is immunocompromised or treated with immunosuppressive medications.
- Non-compensated CHF or hospitalization for CHF (Stage 3-4 NYHA Functional Class) within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled BP (>160/100 mmHg) at screening and prior to randomization at Week -4 (Visit 1).
- Current liver disease, as determined by ALT or AST levels above upper limit of normal at Screening Visit.
- Chronic liver disease.
- Hemoglobin <11 g/dL, neutrophil count <1500 /µl, or platelet count <100,000 /µl.
- Known severe pulmonary fibrosis, bronchiectasis or interstitial pneumonitis.
- eGFR ≤ 40 mL/min/1.73m2 tested at Screening Visit. Kidney transplant or requires dialysis.
- Known intolerance and/or known contraindication to MTX treatment or MTX treatment considered inappropriate
- Has uncontrolled type 2 diabetes at Screening with HbA1c ≥8.5%. Patients with type 1 diabetes will be excluded.
- Has known latent autoimmune diabetes of adult.
- Immunocompromised state, regardless of etiology.
- History or treatment of malignancy in the last 5 years, excluding localized, nonmelanoma skin cancers (e.g. basal or squamous cell)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: E4W with placebo-MTX
IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with placebo-MTX |
intravenous (IV) infusion Oral Placebo-MTX weekly |
|
Eksperimentel: E4W with MTX
IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Eksperimentel: E6W with MTX
IV infusion of PRX-115 every 6 weeks (E6W) for a total of 4 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Eksperimentel: E8W with MTX
IV infusion of PRX-115 every 8 weeks (E8W) for a total of 3 doses with MTX |
intravenous (IV) infusion Oral MTX 15 mg weekly |
|
Placebo komparator: placebo E4W
infusion of PRX-115 placebo every 4 weeks (E4W) for a total of 6 doses with placebo-MTX |
Oral Placebo-MTX weekly intravenous (IV) infusion |
|
Placebo komparator: placebo E6W
IV infusion of PRX-115 placebo every 6 weeks (E6W) for a total of 4 doses with placebo-MTX |
Oral Placebo-MTX weekly intravenous (IV) infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Tidsramme: 6 months of treatment
|
Proportion of patients who achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 6 |
6 months of treatment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) at different time points
Tidsramme: 3 to 6 months of treatment
|
Proportion of patients that achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 3 or 4, 5 and 6. |
3 to 6 months of treatment
|
|
Treatment-emergent adverse events (TEAEs)
Tidsramme: From enrollment to 8 months of study
|
Occurrence and severity of treatment-emergent adverse events (TEAEs) |
From enrollment to 8 months of study
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Krystalarthropatier
- Muskuloskeletale sygdomme
- Patologiske processer
- Gigt
- Ledsygdomme
- Reumatiske sygdomme
- Purin-Pyrimidin metabolisme, medfødte fejl
- Metabolisme, medfødte fejl
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Gigt
- Hyperurikæmi
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Pterins
- Pteridiner
- Aminopterin
- Methotrexat
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PB115-GT-201
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .